These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 28946901)

  • 1. Pre-emptive and therapeutic value of blocking bacterial attachment to the endothelial alphaVbeta3 integrin with cilengitide in sepsis.
    Garciarena CD; McHale TM; Martin-Loeches I; Kerrigan SW
    Crit Care; 2017 Sep; 21(1):246. PubMed ID: 28946901
    [No Abstract]   [Full Text] [Related]  

  • 2. Inhibition of Vascular Endothelial Cell Leak Following Escherichia coli Attachment in an Experimental Model of Sepsis.
    McHale TM; Garciarena CD; Fagan RP; Smith SGJ; Martin-Loches I; Curley GF; Fitzpatrick F; Kerrigan SW
    Crit Care Med; 2018 Aug; 46(8):e805-e810. PubMed ID: 29782355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of major integrin α
    McDonnell CJ; Garciarena CD; Watkin RL; McHale TM; McLoughlin A; Claes J; Verhamme P; Cummins PM; Kerrigan SW
    J Thromb Haemost; 2016 Dec; 14(12):2536-2547. PubMed ID: 27606892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cilengitide inhibits attachment and invasion of malignant pleural mesothelioma cells through antagonism of integrins αvβ3 and αvβ5.
    Cheng NC; van Zandwijk N; Reid G
    PLoS One; 2014; 9(3):e90374. PubMed ID: 24595274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cilengitide targets pediatric glioma and neuroblastoma cells through cell detachment and anoikis induction.
    Leblond P; Dewitte A; Le Tinier F; Bal-Mahieu C; Baroncini M; Sarrazin T; Lartigau E; Lansiaux A; Meignan S
    Anticancer Drugs; 2013 Sep; 24(8):818-25. PubMed ID: 23728220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency.
    Mikkelsen T; Brodie C; Finniss S; Berens ME; Rennert JL; Nelson K; Lemke N; Brown SL; Hahn D; Neuteboom B; Goodman SL
    Int J Cancer; 2009 Jun; 124(11):2719-27. PubMed ID: 19199360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cilengitide, an αvβ3-integrin inhibitor, enhances the efficacy of anti-programmed cell death-1 therapy in a murine melanoma model.
    Pan X; Yi M; Liu C; Jin Y; Liu B; Hu G; Yuan X
    Bioengineered; 2022 Feb; 13(2):4557-4572. PubMed ID: 35142593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blocking αvβ3 integrin by a recombinant RGD disintegrin impairs VEGF signaling in endothelial cells.
    Montenegro CF; Salla-Pontes CL; Ribeiro JU; Machado AZ; Ramos RF; Figueiredo CC; Morandi V; Selistre-de-Araujo HS
    Biochimie; 2012 Aug; 94(8):1812-20. PubMed ID: 22561350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrin alpha v beta 3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models.
    Albert JM; Cao C; Geng L; Leavitt L; Hallahan DE; Lu B
    Int J Radiat Oncol Biol Phys; 2006 Aug; 65(5):1536-43. PubMed ID: 16863930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting αvβ3 and αvβ5 integrins inhibits pulmonary metastasis in an intratibial xenograft osteosarcoma mouse model.
    Gvozdenovic A; Boro A; Meier D; Bode-Lesniewska B; Born W; Muff R; Fuchs B
    Oncotarget; 2016 Aug; 7(34):55141-55154. PubMed ID: 27409827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rational improvement of the affinity and selectivity of integrin binding of grafted lasso peptides.
    Hegemann JD; De Simone M; Zimmermann M; Knappe TA; Xie X; Di Leva FS; Marinelli L; Novellino E; Zahler S; Kessler H; Marahiel MA
    J Med Chem; 2014 Jul; 57(13):5829-34. PubMed ID: 24949551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The inhibitor of integrins Cilengitide: a new active drug in neuro-oncology].
    Leblond P; Meignan S; Le Tinier F; Bethe U; Lansiaux A
    Bull Cancer; 2011 Oct; 98(9):1083-90. PubMed ID: 21914576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrin αvβ3-Akt signalling plays a role in radioresistance of melanoma.
    Im H; Lee J; Ryu KY; Yi JY
    Exp Dermatol; 2020 Jun; 29(6):562-569. PubMed ID: 32298492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design.
    Beekman KW; Colevas AD; Cooney K; Dipaola R; Dunn RL; Gross M; Keller ET; Pienta KJ; Ryan CJ; Smith D; Hussain M
    Clin Genitourin Cancer; 2006 Mar; 4(4):299-302. PubMed ID: 16729916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increasing αvβ3 selectivity of the anti-angiogenic drug cilengitide by N-methylation.
    Mas-Moruno C; Beck JG; Doedens L; Frank AO; Marinelli L; Cosconati S; Novellino E; Kessler H
    Angew Chem Int Ed Engl; 2011 Sep; 50(40):9496-500. PubMed ID: 21948451
    [No Abstract]   [Full Text] [Related]  

  • 16. Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome.
    Weller M; Nabors LB; Gorlia T; Leske H; Rushing E; Bady P; Hicking C; Perry J; Hong YK; Roth P; Wick W; Goodman SL; Hegi ME; Picard M; Moch H; Straub J; Stupp R
    Oncotarget; 2016 Mar; 7(12):15018-32. PubMed ID: 26918452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolism and disposition of the αv-integrin ß3/ß5 receptor antagonist cilengitide, a cyclic polypeptide, in humans.
    Becker A; von Richter O; Kovar A; Scheible H; van Lier JJ; Johne A
    J Clin Pharmacol; 2015 Jul; 55(7):815-24. PubMed ID: 25683324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disruption of integrin-fibronectin complexes by allosteric but not ligand-mimetic inhibitors.
    Mould AP; Craig SE; Byron SK; Humphries MJ; Jowitt TA
    Biochem J; 2014 Dec; 464(3):301-13. PubMed ID: 25333419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Linear and Cyclic Depsipeptidomimetics with β-Lactam Cores: A Class of New α
    Zabala-Uncilla N; Miranda JI; Laso A; Fernández X; Ganboa JI; Palomo C
    Chembiochem; 2017 Apr; 18(7):654-665. PubMed ID: 28140512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cilengitide restrains the osteoclast-like bone resorbing activity of myeloma plasma cells.
    Tucci M; Stucci S; Felici C; Cafforio P; Resta L; Rossi R; Silvestris F
    Br J Haematol; 2016 Apr; 173(1):59-69. PubMed ID: 26728969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.